The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.
“This was only one part, but you can conclude it has a good profile concerning [the] side effects, and it doesn’t have an impact to the adherence of OSA therapy, which is very important."
At the 24th Congress of the European Sleep Research Society in Basel Switzerland, Geert Mayer, MD, a neurologist and sleep specialist at Philipps University of Marburg, sat down with NeurologyLive to discuss one of the many presentations studying solriamfetol (JZP-101), a selective dopamine and norepinephrine reuptake inhibitor, in treatment of excessive sleepiness in narcolepsy and obstructive sleep apnea.
The phase III 12-week study aimed to evaluate whether solriamfetol had a different effect in participants adherent or nonadherent to primary obstructive sleep apnea devices and whether treatment with solriamfetol had an impact on primary therapy use.
The results concluded that there was no impact of the use of solriamfetol on the adherence in both the nonadherent and adherent groups, with no clinically significant changes in device usage throughout the study period. The study did report an Increased sleep latency on the MWT, dose-dependently as seen before, and reduced the score of the Epworth Sleepiness Scale.
To conclude, solriamfetol has proven to be efficacious, is reported with a good safety profile and doesn’t have an impact on the adherence to the obstructive sleep apnea therapy. The FDA will review an application for solriamfetol (JZP-110) in December.